Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2008 1
2010 1
2011 1
2012 1
2013 1
2014 1
2016 1
2020 1
2021 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Hepcidin resistance in dysmetabolic iron overload.
Rametta R, Dongiovanni P, Pelusi S, Francione P, Iuculano F, Borroni V, Fatta E, Castagna A, Girelli D, Fargion S, Valenti L. Rametta R, et al. Among authors: fatta e. Liver Int. 2016 Oct;36(10):1540-8. doi: 10.1111/liv.13124. Epub 2016 Apr 6. Liver Int. 2016. PMID: 26998752
Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades.
Lombardi R, Colavolpe L, Alletto F, Cespiati A, Fatta E, Bertelli C, Cinque F, Pisano G, Pulixi E, Francione P, Maffi G, Iuculano F, Dongiovanni P, Meroni M, Burdick L, Bignamini D, Maggioni M, Valenti L, Fargion S, Fracanzani AL. Lombardi R, et al. Among authors: fatta e. Dig Liver Dis. 2024 Jan;56(1):144-151. doi: 10.1016/j.dld.2023.07.009. Epub 2023 Jul 26. Dig Liver Dis. 2024. PMID: 37507284
Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, Pisano G, Fatta E, Sigon G, Iuculano F, Crapanzano L, Gibilaro G, Francione P, Craxì A, Fargion S, Fracanzani AL. Cespiati A, et al. Among authors: fatta e. Dig Liver Dis. 2021 Oct;53(10):1301-1307. doi: 10.1016/j.dld.2020.11.001. Epub 2020 Nov 17. Dig Liver Dis. 2021. PMID: 33214063
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort.
Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Massari M, Coppola C, Biliotti E, Giorgini A, Laccabue D, Ciancio A, Blanc PL, Margotti M, Ieluzzi D, Brunetto MR, Barbaro F, Russo FP, Beretta I, Morsica G, Verucchi G, Saracino A, Galli M, Kondili LA; PITER Collaborating Group. Quaranta MG, et al. Dig Liver Dis. 2021 Dec;53(12):1603-1609. doi: 10.1016/j.dld.2021.03.020. Epub 2021 Apr 21. Dig Liver Dis. 2021. PMID: 33893040 Free article.
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M; PegBeLiver Study Group. Lampertico P, et al. Gut. 2013 Feb;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2. Gut. 2013. PMID: 22859496 Clinical Trial.
11 results